Cypher Stars In “Real World” Dutch Registry Of High-Risk Patients
This article was originally published in The Gray Sheet
Executive Summary
J&J/Cordis' SISR pivotal trial is comparing the Cypher sirolimus-eluting stent with intravascular brachytherapy for treatment of in-stent restenosis
You may also be interested in...
Brachytherapy Inconvenience Driving Off-Label DES Use – Novoste
Novoste is looking to expanded indications for brachytherapy, such as treatment of arterial-venous dialysis graft occlusions, to overcome competition from vascular stenting
Brachytherapy Inconvenience Driving Off-Label DES Use – Novoste
Novoste is looking to expanded indications for brachytherapy, such as treatment of arterial-venous dialysis graft occlusions, to overcome competition from vascular stenting
Cordis Counters TAXUS IV With “New SIRIUS,” Critiques Angiographic Data
The revascularization rates associated with Boston Scientific's Taxus paclitaxel-eluting stent in TAXUS IV are "artificially" depressed by the relatively low rate of angiographic follow-up in the trial, according to rival Johnson & Johnson/Cordis